RGEN: Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products.
RGEN as a mid-cap is new watch and being saved for own watch list and entry steep right now. 2.4B Mkt Cap and similiar EV. BETA 0.71 so great buy and forget stock. Debt low to cash flow.
Ownership: 80 Institution, 3 Management and insider trend has been sell. Look at chart and ask why?
Q2 Earnings in early Aug. were good, but first time below mkt expectations in awhile....so watching. Q3 E in early Nov-18.
Buylongselllong format courtesy of @MarxBabu. Format changed to add 1w MA and add resistance line for optimal entry. Comments & feedback appreciated especially if you understand the technology by Repligen.